NCT02449018 - A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 27, 2016

Study Completion Date

January 23, 2017

Conditions

Chronic Obstructive Pulmonary Disease, COPD

Interventions

DRUG

QBW251

QBW251 capsule(s) taken orally twice per day

DRUG

Placebo

Matching placebo capsule(s) taken orally twice per day

Trial Locations (16)

28078

Novartis Investigative Site, Huntersville

28152

Novartis Investigative Site, Shelby

29303

Novartis Investigative Site, Spartanburg

29379

Novartis Investigative Site, Union

29681

Novartis Investigative Site, Simpsonville

32127

Novartis Investigative Site, Port Orange

33603

Novartis Investigative Site, Tampa

33765

Novartis Investigative Site, Clearwater

35294

Novartis Investigative Site, Birmingham

61761

Novartis Investigative Site, Normal

63141

Novartis Investigative Site, St Louis

92835

Novartis Investigative Site, Fullerton

97504

Novartis Investigative Site, Medford

06708

Novartis Investigative Site, Waterbury

90-153

Novartis Investigative Site, Lodz

55-050

Novartis Investigative Site, Sobótka